Drug: Avandia
2006 sales: $3.4 billion
Manufacturer: GlaxoSmithKline
Safety concern: “black box;†heart failure, heart attack
Related Articles:
> New Avandia warning 'a muddle'. Report [1]
> Avandia warning, comeback imminent? Report [2]
> Avandia cleared FDA by one vote. Report [3]
> Avandia, Actos don't boost death risk. Report [4]
> FDA adds to drumbeat of bad news for Avandia. Report [5]
> Expert committee says Avandia should stay. Report [6]
> FDA expert wants Avandia withdrawn. Report [7]
> Docs shunning Avandia in wake of safety study. Report [8]
> Avandia risks exposed under deal to post data. Report [9]
Links:
[1] http://www.fiercepharma.com/story/new-avandia-warning-muddle/2007-11-15?utm_medium=rss&utm_source=rss
[2] http://www.fiercepharma.com/story/avandia-warning-comeback-imminent/2007-11-14?utm_medium=nl&utm_source=link
[3] http://www.fiercepharma.com/story/spotlight-avandia-cleared-fda-one-vote/2007-10-30
[4] http://www.fiercepharma.com/story/avandia-actos-dont-boost-death-risk/2007-09-28
[5] http://www.fiercepharma.com/story/fda-adds-to-drumbeat-of-bad-news-for-avandia/2007-08-15?utm_medium=nl&utm_source=link
[6] http://www.fiercebiotech.com/story/expert-committee-says-avandia-should-stay/2007-07-31
[7] http://www.fiercebiotech.com/story/fda-expert-wants-avandia-withdrawn/2007-07-30
[8] http://www.fiercebiotech.com/story/docs-shunning-avandia-in-wake-of-safety-study/2007-05-29
[9] http://www.fiercebiotech.com/story/avandia-risks-exposed-under-deal-to-post-data/2007-05-23
[10] http://www.fiercepharma.com/special-reports/3-zyprexa-top-10-warnings-and-recalls
[11] http://www.fiercepharma.com/special-reports/top-10-drug-warnings-and-recalls-2007
[12] http://www.fiercepharma.com/special-reports/5-actos-top-10-warnings-and-recalls